Strategic Life Sciences Advisory
Three decades of pharmaceutical leadership — from clinical development to global market access — now dedicated to guiding the next generation of therapeutic innovation.
About
MD, PhD · Board-Certified Physician · Adjunct Professor
With a career spanning executive leadership at Nestlé Health Science and Boehringer Ingelheim, Dr. Woerle brings a rare combination of deep scientific expertise and strategic business acumen to every engagement.
As former Chief Medical & Scientific Officer at Nestlé Health Science, he directed global R&D strategy and clinical development across the medical nutrition portfolio. At Boehringer Ingelheim, he served as Vice President for Metabolism, where he was the architect and patent inventor of the landmark EMPA-REG OUTCOME trial — the first cardiovascular outcome trial to demonstrate a mortality benefit in type 2 diabetes.
He holds an MD and PhD from Ludwig Maximilian University of Munich, serves as Adjunct Professor at the University of Ulm, and has authored over 200 peer-reviewed publications.
Expertise
Deep domain expertise across the full pharmaceutical value chain, from early research to global commercialisation.
Pioneering work in SGLT2 inhibitor cardiovascular outcomes, type 2 diabetes, obesity, and metabolic rare diseases.
End-to-end clinical programme design, regulatory strategy, and evidence generation for global registrations.
Building and leading global medical affairs organisations, KOL engagement, and publication strategy.
Strategic oversight and board governance in microbiome-based therapies, enzyme therapeutics, and medical nutrition.
Independent board directorship for public and private companies across the global life sciences landscape.
Portfolio prioritisation, pipeline valuation, and strategic resource allocation across therapeutic areas.
Services
Flexible engagement models tailored to the strategic needs of pharmaceutical, biotech, and medical device companies.
Retained advisory engagements for C-suite and board-level strategic decision-making in clinical development, regulatory affairs, and portfolio strategy.
Independent board membership and scientific advisory board leadership for public and private life sciences companies.
Scientific and clinical due diligence for investment decisions, M&A transactions, and licensing opportunities.
Clinical trial design, endpoint strategy, and regulatory pathway planning for novel therapeutic programmes.
Affiliations
Board Director
NASDAQ: MCRB · Microbiome therapeutics
Board Director
Neurological diseases · Brain energy metabolism
Board Director
Microbiome-based immunology · Oncology
Contact
Whether you are seeking advisory support for a clinical programme, evaluating a strategic investment, or looking for experienced board-level leadership, I welcome the opportunity to explore how we can work together.